Editas, Genevant Sciences

Editas and Genevant team up to develop gene editing therapies
Editas is partnering its CRISPR platform with Genevant’s LNP technology to develop novel gene editing medicines in a deal worth $283m.
EDIT Inks Collaboration Deal to Develop Novel Gene Editing Therapies
Editas Medicine, Inc. EDIT announced that it has entered into a collaboration and nonexclusive license agreement with Canada-based privately held company Genevant Sciences to develop in vivo gene editing medicines.
Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics
CAMBRIDGE, Mass. and VANCOUVER, British Columbia and BASEL, Switzerland, Oct. 21, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: EDIT), a clinical-stage gene editing company, and Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio,
Editas Medicine, Genevant Sciences enter collaboration and license agreement
Editas Medicine (EDIT) and Genevant Sciences announced that they have entered into a collaboration and nonexclusive license agreement to
Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing ...
CAMBRIDGE, Mass. and VANCOUVER, British Columbia and BASEL, Switzerland, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, and Genevant Sciences,
Roivant Sciences: Good Value, But Near-Term Catalysts Could Bring Volatility
Roivant's high valuation is justified, with a strong cash position, promising drug pipeline, and strategic partnerships ...
FierceBiotech1d
Editas prioritizes in vivo gene therapies, looks to partner reni-cel
Editas Medicine is pushing its in vivo gene therapy strategy to the top of its agenda, boasting proof-of-concept data and ...
BioPharma Dive1d
Editas, changing course again, looks to partner lead CRISPR therapy
The gene editing company will focus on “in vivo” medicines, while seeking to license out or find a development partner for ...
BioWorld27d
Repair Biotechnologies and Genevant Sciences collaborate on mRNA-LNP therapy for atherosclerosis
Repair Biotechnologies Inc. and Genevant Sciences Corp. have entered into a collaboration and nonexclusive license agreement to combine Repair’s Cholesterol Degrading Platform (CDP) mRNA technology ...
FierceBiotech27d
Repair licenses Genevant's nucleic acid delivery tech for up to $107M per cardio product
Syracuse, New York-based Repair Biotechnologies will use Swiss company Genevant’s lipid nanoparticles to usher its cholesterol-degrading mRNA to atherosclerosis plaques, the companies announced ...
Editas Medicine, Inc.: Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics
CAMBRIDGE, Mass. and VANCOUVER, British Columbia and BASEL, Switzerland, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, and Genevant Sci ...